Q2 2024 Nektar Therapeutics Earnings Call Transcript
Good day and thank you for standing by. Welcome to the Nektar Therapeutics second-quarter 2024 financial results conference call. (Operator Instructions) Please be advised that today's call is being recorded.
I would now like to hand the conference over to your speaker today, Vivian Wu. Please go ahead.
Thank you, Crystal, and good afternoon, everyone. Thank you for joining us today. With us on the call are Howard Robin, our President and Chief Executive Officer; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; Dr. Mary Tagliaferri, our Chief Medical Officer; and Sandra Gardiner, our Chief Financial Officer. On today's call, we expect to make forward-looking statements regarding our business, including statements regarding the therapeutic potential of and future development plans for drug candidates and research programs.
The timing of the initiation of clinical studies and the availability of clinical data for drug candidates, the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |